Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06194461 · ClinicalTrials.gov registry record
LTFU for All Cell and Gene Therapy Studies
A clinical trial, sponsored by AstraZeneca.
- Not yet
- Registry status
- 64
- Enrollment target
NCT06194461: Clinical Trial study, sponsored by AstraZeneca.
NCT06194461 is a clinical trial that has not yet begun recruiting, run by AstraZeneca. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06194461 has not yet begun recruiting, sponsored by AstraZeneca.
- NOT YET RECRUITING
- Registry status
- 64 participants
- Enrollment target
Study Summary
Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.
Primary Outcome
To determine long-term safety of previous treatment with applicable cell and gene therapy products
Interventions
- BIOLOGICAL AZD0754
- BIOLOGICAL AZD5851
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2025-09-17 |
| Est. Completion | 2041-11-29 |
What is known before NCT06194461 opens enrollment
NCT06194461 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which AZD0754 is the first listed.
NCT06194461 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06194461 about?
NCT06194461 is a clinical study titled "LTFU for All Cell and Gene Therapy Studies". Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.
What is the current status of trial NCT06194461?
This trial is currently not yet recruiting. The enrollment target is 64 participants. The study started on 2025-09-17. Estimated completion is 2041-11-29.
What interventions are being tested in trial NCT06194461?
The interventions under investigation include: AZD0754 (BIOLOGICAL), AZD5851 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06194461?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI